Imugene Reveals Dispersed Ownership Across 2027 Listed Options

An update from Imugene ( (AU:IMU) ) is now available.

Imugene has released a top holders report for its listed options series IMUOPT41, which are exercisable at $0.18 and expire on 30 April 2027, showing a diverse register dominated by nominee and custodial entities. Citicorp Nominees is the largest holder with 5.58% of the options on issue, followed by Finclear Services and HSBC Custody Nominees, while a wide spread of individual and superannuation fund investors each hold identical parcels of 206,896 options, underlining a highly dispersed but structurally coordinated investor base.

The report indicates that, beyond the top three custodial holders, no single investor controls a significant proportion of the IMUOPT41 series, which may support liquidity but limits the influence of any one stakeholder in corporate actions tied to this option line. The concentration of many small but uniform holdings among private investors and self-managed super funds suggests strong retail engagement with Imugene’s derivatives, reflecting ongoing speculative and strategic interest in the company’s future share price performance.

The most recent analyst rating on (AU:IMU) stock is a Buy with a A$0.82 price target. To see the full list of analyst forecasts on Imugene stock, see the AU:IMU Stock Forecast page.

More about Imugene

Imugene Limited is an Australian biotechnology company focused on developing immuno-oncology therapies, with its securities listed on the Australian Securities Exchange. The company attracts a mix of institutional, custodial and retail investors who actively trade its shares and listed options as part of broader exposure to the biotech and life sciences sector.

Average Trading Volume: 1,591,716

Technical Sentiment Signal: Strong Sell

Current Market Cap: A$48.37M

Learn more about IMU stock on TipRanks’ Stock Analysis page.